CA2438899A1 - Procede de determination de l'efficacite d'agents stimulateurs du transport inverse du cholesterol - Google Patents

Procede de determination de l'efficacite d'agents stimulateurs du transport inverse du cholesterol Download PDF

Info

Publication number
CA2438899A1
CA2438899A1 CA002438899A CA2438899A CA2438899A1 CA 2438899 A1 CA2438899 A1 CA 2438899A1 CA 002438899 A CA002438899 A CA 002438899A CA 2438899 A CA2438899 A CA 2438899A CA 2438899 A1 CA2438899 A1 CA 2438899A1
Authority
CA
Canada
Prior art keywords
test agent
protein
rct
agent
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438899A
Other languages
English (en)
Inventor
Samuel D. Wright
Tian-Quan Cai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2438899A1 publication Critical patent/CA2438899A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé de criblage et/ou de détermination de l'efficacité de composés connus ou potentiels de stimulation du transport inverse du cholestérol chez les mammifères. Ce procédé s'affranchit de la mesure des taux d'ARNm ou des protéines cellulaires et se base plutôt sur les mesures des taux de CD14 dans le sang.
CA002438899A 2001-02-21 2002-02-19 Procede de determination de l'efficacite d'agents stimulateurs du transport inverse du cholesterol Abandoned CA2438899A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27035601P 2001-02-21 2001-02-21
US60/270,356 2001-02-21
PCT/US2002/005722 WO2002067958A1 (fr) 2001-02-21 2002-02-19 Procede de determination de l'efficacite d'agents stimulateurs du transport inverse du cholesterol

Publications (1)

Publication Number Publication Date
CA2438899A1 true CA2438899A1 (fr) 2002-09-06

Family

ID=23030997

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438899A Abandoned CA2438899A1 (fr) 2001-02-21 2002-02-19 Procede de determination de l'efficacite d'agents stimulateurs du transport inverse du cholesterol

Country Status (4)

Country Link
EP (1) EP1401456A4 (fr)
JP (1) JP2004527737A (fr)
CA (1) CA2438899A1 (fr)
WO (1) WO2002067958A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013096A1 (fr) * 1993-11-08 1995-05-18 Peptide Delivery Systems Pty. Ltd. Compositions de diagnostic marquees et leurs procedes d'utilisation
DE69829293T2 (de) * 1997-04-02 2006-04-13 The Brigham And Women's Hospital Inc., Boston Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen
US6120994A (en) * 1997-05-23 2000-09-19 Queen's University At Kingston Antioxidant responsive element

Also Published As

Publication number Publication date
EP1401456A1 (fr) 2004-03-31
EP1401456A4 (fr) 2005-04-20
WO2002067958A1 (fr) 2002-09-06
JP2004527737A (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
Thieringer et al. Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo
Berger et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator
Van Wijk et al. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes
Kurtz et al. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system
Mudaliar et al. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers
Davies et al. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-γ expression in hepatocytes
Han et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator–activated receptor γ
Ghosh et al. Disruption of transforming growth factor β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator–activated receptor γ
Letavernier et al. Peroxisome proliferator-activated receptor β/δ exerts a strong protection from ischemic acute renal failure
Yamauchi et al. Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes
Westhuyzen et al. Biology and relevance of C-reactive protein in cardiovascular and renal disease
JP5758298B2 (ja) 非アルコール性脂肪肝炎関連マーカー
Hattori et al. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells
Harrity et al. Muraglitazar, a novel dual (α/γ) peroxisome proliferator–activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β-cell function in db/db mice
Rothe et al. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease
Schlezinger et al. Peroxisome proliferator-activated receptor γ-mediated NF-κB activation and apoptosis in pre-B cells
Carmona et al. S 26948: a New Specific Peroxisome Proliferator–Activated Receptor γ Modulator With Potent Antidiabetes and Antiatherogenic Effects
Orfila et al. Immunohistochemical distribution of activated nuclear factor κB and peroxisome proliferator-activated receptors in carbon tetrachloride-induced chronic liver injury in rats
Hu et al. Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle
Kolovou et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 expert panel statement, narrative review
Kamo et al. Impact of FDA-approved drugs on the prostaglandin transporter OATP2A1/SLCO2A1
Xu et al. Myeloid‐derived growth factor (MYDGF) protects bone mass through inhibiting osteoclastogenesis and promoting osteoblast differentiation
Cignarella et al. Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors
Karasek et al. Prothrombotic markers in asymptomatic dyslipidemic subjects
Goebel et al. Effective treatment of hypertension by AT1 receptor antagonism: the past and future of telmisartan

Legal Events

Date Code Title Description
FZDE Discontinued